Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...

Novartis increased sales by 15 percent to USD 13.2 billion in the fourth quarter of 2024. Profit rose by 7 percent to USD 2.8 ...

Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...

Taco Bell says the fans are the real stars of their 2025 Big Game ad. If customers took a photo at one of the chain's Live ...

Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...

Earnings season marches on, and we're here to spotlight the companies set to unveil their financial results in the next trading day. As Friday approaches, investors are eagerly anticipating reports ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.